HRAS Stably Expressing Transformed NIH/3T3 Cell Line (GhrasT-NIH/3T3)

Unit

1×10⁶ cells / 1.0 ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Embryo

Organism

Mouse (M. musculus)

Donor History

NIH/3T3

Growth Properties

Adherent

,

fibroblast

Growth Conditions

PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Dulbecco's Modified Eagle Medium (DMEM)

,

High Glucose (TM500) + 10% FBS + 1% Penicillin/Streptomycin Solution (G255)

,

37.0°C

,

5% CO₂.

Immortalization Method
Full Information

https://www.abmgood.com/HRAS-Stably-Expressing-NIH-3T3-Cell-Line-GhrasT-NIH-3T3-t3317.html

Katalogové číslo: T3317 Kategorie: ,
Popis

This transformed (cancerous) cell line was established from transfecting the well-known NIH/3T3 (Cat. T8981) cell line with the Harvey-ras (HRAS) oncogene isolated from T24 human bladder carcinoma. This cell line was injected s.c. into NIH Swiss mice to produce primary tumors. This cell line, GhrasT-NIH/3T3, is the parental transformed cell for catalogs T8144 to T8147.These cells are tumorigenic. This cell line is part of an eight cell R/J Model of Metastatic Progression designed using the NIH Swiss mice species to acquire isogenic cell types (T4138, T8981,T3317, T8144-T8148) that capture genetic/phenotypic stages in the progression to highly metastatic growth within this same species. Compared to some other models, the metastasis related changes captured in this unique progression model are easier to discern above their less noisy isogenic background and have progressed within their native NIH Swiss in vivo micro-environments. This isogenic R/J Metastasis Cell Model was produced by an in vitro/in vitro six-step progression from mortal normal NIH Swiss mouse cells (Cat. T4138) that were used to produce immortal pre-cancer NIH/3T3 cells (Cat. T8981) that were transfected with the human HRAS oncogene to produce transformed cancer GhrasT-NIH/3T3 cells (Cat. T3317). Then beginning with a series of in vivo/in vitro progressive transfers of GhrasT-NIH/3T3 cells produced primary tumor T1-A cells (Cat. T8144) that produced local metastatic lesion T2-A cells (Cat. T8145) that simultaneously produced twin distant metastatic lung lesion T3-PA cells (Cat. T8146) with its twin distant metastatic liver lesion cells (Cat. T1847). The liver derived cells produced highly distant metastatic lung lesion cells (Cat T1848) which retained the human HRAS oncogene and they demonstrated a highly metastatic phenotype as they produced wide-spread simultaneous external and internal metastases in multiple sites in multiple mice when injected i.v. into nude NIH Swiss mice.Complete list of cells included in the R/J Metastasis Model:Cat. T8981 – NIH-3T3 CellsCat. T4138 – Normal Primary Diploid Mortal NIH Swiss Mouse Embryonic CellsCat. T3317 – HRAS Stably Expressing Transformed NIH/3T3 Cell Line (GhrasT-NIH/3T3)Cat. T8144 – Primary Tumor Cell Line (T1-A )Cat. T8145 – Local Metastasis Tumor Cell Line (T2-A)Cat. T8146 – Distant Pulmonary Metastasis Tumor Cell Line (T3-PA)Cat. T8147 – Distant Hepatic Metastasis Tumor Cell Line (T3-HA)Cat. T8148 – Highly Metastatic Distant Pulmonary Tumor Cell Line (T4-PA)

O značce
Applied Biological Materials (abm) je jedním z našich klíčových dodavatelů pro biotechnologický průmysl. Společnost byla založena v roce 2004 a již více než deset let podporuje vědecké objevy v oblasti přírodních věd a vývoje léčiv. Její sídlo se nachází ve Vancouveru v Kanadě. ABM je pro nás neocenitelným partnerem zejména v  oblasti dodávek buněčných kultur, genových a virových vektorů, produktů pro molekulární biologii a PCR, nástrojů pro technologie CRISPR a RNAi, protilátek i základních reagencií pro molekulárně genetické procesy.